Royalty Pharma PLC Class A RPD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- €49.25
- Day Range
- €49.87–50.43
- 52-Week Range
- —–54.38
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 445.28M
- Market Cap
- £22.21B
- Volume/Avg
- — / 41
Key Statistics
- Price/Earnings (Normalized)
- 38.77
- Price/Sales
- 12.64
- Dividend Yield (Trailing)
- 1.62%
- Dividend Yield (Forward)
- 1.64%
- Dividend Payment Schedule
- Mar, Jun, Sep, Dec
- Total Yield
- 2.84%
Company Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Value
- Total Number of Employees
- 100
- Website
- https://www.royaltypharma.com
Competitors
Valuation
|
Metric
|
RPD
|
VRTX
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 38.77 | 26.80 | 9.27 |
Price/Book Value | 3.67 | 6.38 | 1.89 |
Price/Sales | 12.64 | 10.38 | 2.54 |
Price/Cash Flow | 10.78 | 26.34 | 10.52 |
Price/Earnings
RPD
VRTX
PFE
Financial Strength
|
Metric
|
RPD
|
VRTX
|
PFE
|
|---|---|---|---|
Quick Ratio | 2.79 | 2.54 | 0.85 |
Current Ratio | 2.80 | 3.19 | 1.27 |
Interest Coverage | 4.67 | — | 2.36 |
Quick Ratio
RPD
VRTX
PFE
Profitability
|
Metric
|
RPD
|
VRTX
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | −3.59% | 18.99% | 8.46% |
Return on Equity (Normalized) | −10.56% | 26.29% | 19.70% |
Return on Invested Capital (Normalized) | −1.95% | 21.93% | 12.66% |
Return on Assets
RPD
VRTX
PFE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^%!#>Cf | LOCK|XH#Z | $129B | |||
| Moderna Inc
MRNA
| LOCK|&&KSLr | LOCK|fw@ | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!qxq^?y | LOCK|@^>bt | $77B | |||
| argenx SE ADR
ARGX
| LOCK|c$M<%% | LOCK|VN | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Mk!<&XV | LOCK|># | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|d&MJW&y | LOCK|WkKR@ | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>?tk%>!Z | LOCK|F>GX | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|%Gw&MpN | LOCK|ZH | $24B | |||
| Incyte Corp
INCY
| LOCK|^gprqd | LOCK|w<S | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%skS^W& | LOCK|J?$ | $14B |
United States